Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Study: Enbrel Safe After Six-Month Treatment For Rheumatoid Arthritis SEATTLE, April 11, 1997-- Preliminary results from an ongoing safety trial for Enbrel(TM) suggest that the drug can be safely administered to patients with rheumatoid arthritis for six months. Enbrel is a soluble (free-floating) tumor necrosis factor receptor (TNFR) and part of a new class of biologic drugs aimed at inhibiting the biological effects of TNF. Study results were reported today at the regional American College of Rheumatology Meeting in Chicago by Investigator Larry W. Moreland, MD, of the University of Alabama at Birmingham. "This trial has so far shown that TNF receptor can be given safely to patients for six months with infrequent and tolerable side effects," said Dr. Moreland. "This is important for patients with a chronic disease like rheumatoid arthritis." The ongoing, open-label, multi-center study is designed to measure the long-term safety of Enbrel and clinical effects as determined by improvements in tender and swollen joints. Improvements in clinical endpoints were consistent with previously reported results. Forty-one patients received the drug for at least six months in this trial. All patients had previously received the drug for a maximum of three months in earlier clinical trials. Injection site reactions, which are seen with some biologic drugs, were relatively mild and infrequent (146 injection site reactions out of a total 3,708 injections given). Sixteen of 41 patients reported infections (including colds) during 260 patient months of treatment. All infections resolved and no patient withdrew from the study due to injection site reactions or infections. No antibodies against the drug were detected. This long-term safety study continues. Patients on the study are scheduled to receive the drug for a minimum of one year. This study is part of the company's clinical development program in rheumatoid arthritis. Immunex Corporation, who developed the drug, is a biopharmaceutical company engaged in developing immune system science to protect human health. E-mail this page to a friend or colleague! To print, use this version